Literature DB >> 20571802

Inverse mismatch and lesion growth in small subcortical ischaemic stroke.

Jochen B Fiebach1, Alexander Hopt, Tomislav Vucic, Peter Brunecker, Christian H Nolte, Claudia Doege, Kersten Villringer, Gerhard J Jungehulsing, Claudia Kunze, Susanne Wegener, Arno Villringer.   

Abstract

OBJECTIVE: Infarction typically develops within the borders of an initial hypoperfused tissue. We prospectively investigated whether in small subcortical stroke patients infarct growth can occur beyond the margins of the affected vascular territories.
METHODS: In 19 consecutive patients, stroke MRI was performed within 14 h after ictus, and at days 2 and 6 (± 1). Size of diffusion and perfusion disturbances were determined. Infarct volume measured on T2-weighted images on day 6 was considered as imaging endpoint.
RESULTS: At the initial examination, the mean diffusion lesion [apparent diffusion coefficient (ADC) lesion size, 1.82 ± 1.2 ml] was larger (p = 0.0002) than the perfusion lesion [mean transit time (MTT) lesion size, 0.72 ± 0.69 ml]. Such an "inverse mismatch" (ADC lesion > MTT lesion) was present in 14/19 patients at baseline and in all patients on day 2. Final lesion volume at day 6 was 3.2 ± 1.6 ml which was larger than the initial perfusion deficit (p = 0.02).
CONCLUSION: In small subcortical ischaemic stroke "inverse mismatch" is frequent and infarction develops beyond the initial perfusion disturbance. This indicates that cytotoxic processes probably triggered by the infarct core are a dominant mechanism for lesion growth. Areas with normal perfusion but which are threatened by cytotoxic damage developing over several days seem prime targets for neuroprotective therapy.

Entities:  

Mesh:

Year:  2010        PMID: 20571802     DOI: 10.1007/s00330-010-1858-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

1.  High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis.

Authors:  L Ostergaard; R M Weisskoff; D A Chesler; C Gyldensted; B R Rosen
Journal:  Magn Reson Med       Date:  1996-11       Impact factor: 4.668

2.  The arterial lesions underlying lacunes.

Authors:  C M Fisher
Journal:  Acta Neuropathol       Date:  1968-12-18       Impact factor: 17.088

3.  Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging.

Authors:  A E Baird; A Benfield; G Schlaug; B Siewert; K O Lövblad; R R Edelman; S Warach
Journal:  Ann Neurol       Date:  1997-05       Impact factor: 10.422

4.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Authors:  Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

5.  Which time-to-peak threshold best identifies penumbral flow? A comparison of perfusion-weighted magnetic resonance imaging and positron emission tomography in acute ischemic stroke.

Authors:  J Sobesky; O Zaro Weber; F-G Lehnhardt; V Hesselmann; A Thiel; C Dohmen; A Jacobs; M Neveling; W-D Heiss
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

6.  Reversal of perfusion and diffusion abnormalities after intravenous thrombolysis for a lacunar infarction.

Authors:  Julio A Chalela; Mustapha Ezzeddine; Lawrence Latour; Steven Warach
Journal:  J Neuroimaging       Date:  2003-04       Impact factor: 2.486

7.  Prospective study of single and multiple lacunar infarcts using magnetic resonance imaging: risk factors, recurrence, and outcome in 175 consecutive cases.

Authors:  Antonio Arauz; Luis Murillo; Carlos Cantú; Fernando Barinagarrementeria; Jesús Higuera
Journal:  Stroke       Date:  2003-09-18       Impact factor: 7.914

8.  The size of subcortical ischemic infarction in patients with and without diabetes mellitus.

Authors:  B N Mankovsky; J T Patrick; B E Metzger; J L Saver
Journal:  Clin Neurol Neurosurg       Date:  1996-05       Impact factor: 1.876

9.  Lacunar stroke is the major cause of progressive motor deficits.

Authors:  Wolfgang Steinke; Stephan C Ley
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

10.  Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study.

Authors:  W T Longstreth; C Bernick; T A Manolio; N Bryan; C A Jungreis; T R Price
Journal:  Arch Neurol       Date:  1998-09
View more
  5 in total

1.  Magnetic resonance diffusion-perfusion mismatch in acute ischemic stroke: An update.

Authors:  Feng Chen; Yi-Cheng Ni
Journal:  World J Radiol       Date:  2012-03-28

2.  Perfusion-weighted imaging and dynamic 4D angiograms for the estimation of collateral blood flow in lacunar infarction.

Authors:  Alex Förster; Bettina Mürle; Johannes Böhme; Mansour Al-Zghloul; Hans U Kerl; Holger Wenz; Christoph Groden
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-14       Impact factor: 6.200

3.  Examining Subcortical Infarcts in the Era of Acute Multimodality CT Imaging.

Authors:  Mindy Y Q Tan; Shaloo Singhal; Henry Ma; Ronil V Chandra; Jamie Cheong; Benjamin B Clissold; John Ly; Velandai Srikanth; Thanh G Phan
Journal:  Front Neurol       Date:  2016-12-05       Impact factor: 4.003

4.  Association of compromised cerebral perfusion with lenticulostriate artery impairments in the subacute phase of branch atheromatous disease.

Authors:  Shuai Jiang; Jing-Yu Cui; Yu-Ying Yan; Tang Yang; Wen-Dan Tao; Bo Wu
Journal:  Ther Adv Neurol Disord       Date:  2022-07-04       Impact factor: 6.430

5.  Diffusion- and perfusion-weighted imaging in acute lacunar infarction: is there a mismatch?

Authors:  Alex Förster; Hans Ulrich Kerl; Holger Wenz; Marc A Brockmann; Ingo Nölte; Christoph Groden
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.